Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invested in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The Company's portfolio consists of pharmaceutical products with molecules and includes both in-licensed products, such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome as well as products owned (or partially owned) by it, such as Exelon and Impavido.


TSX:GUD - Post by User

Bullboard Posts
Comment by porksnifferon Aug 08, 2018 4:12pm
118 Views
Post# 28429652

RE:Don’t understand

RE:Don’t understand
Lookingforclues wrote: Why are VRX and ENDP rising is price with such huge debt loads.
I was reading that they will never be able to reduce said Debt.
So how come?   That is putting it in very plain language!




I'll explain it to you. What your reading about VRX and ENDP never being able to reduce their debt is a bunch of horseshitt. Valeant has gone from $33 billion to $25.5 billion. They've paid down over $7 billion since 1Q/16. Just last week they paid 150 million. They pay as cash flow comes in. They also have no debt payments upcoiming until 2021. ENDP has stabalized and net debt is dropping. You may have forgotten these are cash flow machines. Valeant can cash flow over 2 billion dollars despite interest payments of $1.6 billion. Every billion that gets paid down becomes equity and the stock price rises accordingly. There is no point in hoarding cash and being totally underleveraged. The disaster management was certain to happen, didn't happen. I hope this is putting it in plain language for you.
Bullboard Posts